Ascendis Pharma A/S’s (ASND) “Outperform” Rating Reaffirmed at Wedbush

Wedbush reaffirmed their outperform rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a report published on Friday morning, MarketBeat.com reports. Wedbush currently has a $181.00 price objective on the biotechnology company’s stock.

Other analysts have also recently issued reports about the stock. The Goldman Sachs Group increased their price objective on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Evercore ISI raised their price target on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a report on Tuesday, September 17th. Wells Fargo & Company boosted their price objective on Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Citigroup increased their target price on Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Finally, JPMorgan Chase & Co. lowered their price target on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a report on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $191.77.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND traded up $2.23 during midday trading on Friday, hitting $126.51. The company had a trading volume of 1,448,861 shares, compared to its average volume of 450,130. Ascendis Pharma A/S has a 12-month low of $90.13 and a 12-month high of $161.00. The company has a fifty day moving average of $132.30 and a two-hundred day moving average of $132.70. The company has a market cap of $7.67 billion, a price-to-earnings ratio of -13.59 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. Research analysts expect that Ascendis Pharma A/S will post -7.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Westfield Capital Management Co. LP raised its stake in Ascendis Pharma A/S by 3.4% during the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock valued at $766,523,000 after purchasing an additional 170,942 shares in the last quarter. Avoro Capital Advisors LLC raised its position in shares of Ascendis Pharma A/S by 5.8% during the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after buying an additional 229,995 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Ascendis Pharma A/S by 6.8% in the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after acquiring an additional 267,881 shares during the last quarter. Capital International Investors lifted its holdings in shares of Ascendis Pharma A/S by 0.5% in the 1st quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock valued at $331,261,000 after acquiring an additional 10,044 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its position in Ascendis Pharma A/S by 9.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock worth $278,760,000 after acquiring an additional 155,971 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.